RCSV, SO and ABCT Joint Research Seminar
Research Institute / Research Centre Seminar
-
Date
15 Oct 2024
-
Organiser
Research Centre for SHARP Vision (RCSV); School of Optometry (SO); Department of Applied Biology and Chemical Technology (ABCT)
-
Time
14:00 - 15:30
-
Venue
M1603
Speaker
Prof. Michael Snyder
Dr Zhou Xin
Enquiry
Ms Shirley NG (852) 3400 2312 info.rcsv@polyu.edu.hk
Summary
Session 1
Our present healthcare system focuses on treating people when they are ill rather than keeping them healthy. We have been using big data and remote monitoring approaches to monitor people while they are healthy to keep them that way and detect disease at its earliest moment presymptomatically. We use advanced multiomics technologies (genomics, immunomics, transcriptomics, proteomics, metabolomics, microbiomics) as well as wearables and microsampling for actively monitoring health. Following a group of 109 individuals for over 13 years revealed numerous major health discoveries covering cardiovascular disease, oncology, metabolic health and infectious disease. We have also found that individuals have distinct aging patterns that can be measured in an actionable period of time. Finally, we have used wearable devices for early detection of infectious disease, including COVID-19 as well as microsampling for monitoring and improving lifestyle. We believe that advanced technologies have the potential to transform healthcare and keep people healthy.
Session 2
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated blood pressure in the pulmonary arteries, leading to right heart failure and death. Idiopathic PAH (iPAH), a subtype that develops spontaneously, is frequently associated with a pronounced inflammatory signature. In this study, we profiled peripheral blood mononuclear cells (PBMCs) and conventional dendritic cells (cDCs) from a cohort of iPAH patients, generating a high-quality single-cell dataset of 100,000 cells. Our analysis revealed immune dysregulation phenotypes linked to altered host-microbiome interactions, including decreased CD14 expression on monocytes, driving them towards an apoptotic phenotype, and a viral signature in cDCs associated with responses to human endogenous retrovirus K (HERV-K). These immune alterations corresponded with significant changes in circulating lymphocytes, notably a decrease in natural killer (NK) cells, an increase in regulatory CD4+ T cells, and a shift in the CD8+ T cell population, with a higher memory-to-naive cell ratio. Transcriptomic comparisons further uncovered a global signature of interferon-related signaling activation, aberrant cell migration, reduced NK and CD8+ T cell cytotoxicity, and altered cellular metabolism. These findings advance our understanding of the inflammatory landscape in PAH and identify potential therapeutic targets to address lymphocyte-associated pathology in this disease.
Keynote Speaker
Prof. Michael Snyder
Chair, Department of Genetics; Director, Centre for Genomics and Personalized, School of Medicine, Stanford University
Snyder Lab was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of-the-art "omics" technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. Dr. Snyder is the cofounder of Personalis, SensOmics, Qbio @qbioinc, January AI, Filtricine, Mirvie, Protos, Protometrix (now part of Thermo-Fisher). Affomix (now part of Illumina). Dr. Snyder presently serves on the board of a number of companies. Dr Snyder is the author of the book: 'Genomics and Personalized Medicine: What Everyone Needs to Know'.
Dr Zhou Xin
Postdoctoral Fellow, Michael Snyder Lab, Stanford University
Xin Zhou is a Research Scientist at the Stanford University School of Medicine. He earned his Ph.D. under the mentorship of George Weinstock and completed his postdoctoral training with Michael Snyder. Xin's research focuses on host-microbial interactions in health and disease. He has published 28 research papers, including Cell Host & Microbe (Cover Story) and Circulation Research. His work has been cited over 1100 times. Xin has received several grants including the NIA Resource Centers for Minority Aging Research Fellowship, the Bill & Melinda Gates Foundation grant through Stanford Innovative Medicines Accelerator etc. Xin serves as reviewers for several journals such as National Science Review and Molecular Psychiatry.